Matthew Biegler
Stock Analyst at Oppenheimer
(2.02)
# 3,051
Out of 5,050 analysts
82
Total ratings
38.36%
Success rate
-5.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $12.31 | +127.46% | 3 | Oct 10, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $23 | $12.15 | +89.30% | 1 | Sep 4, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $22 | $8.35 | +163.47% | 7 | Sep 3, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.88 | +325.53% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $3.62 | +93.37% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.18 | +662.71% | 2 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $12.35 | -2.83% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $18.70 | +755.61% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $10.63 | +323.33% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $118.84 | -3.23% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $30.24 | +75.26% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $14.32 | +130.45% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.28 | +1,462.50% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.05 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.87 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $7.63 | +83.49% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $8.87 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.07 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.73 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.96 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.78 | - | 2 | Dec 22, 2022 |
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $12.31
Upside: +127.46%
BridgeBio Oncology Therapeutics
Sep 4, 2025
Initiates: Outperform
Price Target: $23
Current: $12.15
Upside: +89.30%
Olema Pharmaceuticals
Sep 3, 2025
Maintains: Outperform
Price Target: $22
Current: $8.35
Upside: +163.47%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.88
Upside: +325.53%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $3.62
Upside: +93.37%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.18
Upside: +662.71%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $12.35
Upside: -2.83%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $18.70
Upside: +755.61%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $10.63
Upside: +323.33%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $118.84
Upside: -3.23%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $30.24
Upside: +75.26%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $14.32
Upside: +130.45%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.28
Upside: +1,462.50%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $6.05
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.87
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $7.63
Upside: +83.49%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $8.87
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.07
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.73
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.96
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.78
Upside: -